Opportunity Information: Apply for PAR 14 254
Apply for PAR 14 254
- The National Institutes of Health in the education food and nutrition health sector is offering a public funding opportunity titled "Multidisciplinary Studies of HIV and Viral Hepatitis Co Infection (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jun 10, 2014 and posted on Jun 10, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $275,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $275,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Independent school districts City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) County governments Public housing authorities/Indian housing authorities State governments Special district governments For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH grant opportunity titled "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R21)" (Funding Opportunity Number PAR-14-254) is a discretionary research grant designed to support exploratory, early-stage projects that address key unanswered questions about people living with both HIV and viral hepatitis. The central aim of the announcement is to close important scientific and clinical knowledge gaps in three connected areas: first, how HIV and hepatitis viruses interact biologically in the body in ways that may worsen disease; second, what additional health conditions and complications tend to occur in co-infected individuals and why; and third, how well newer interferon-free, direct-acting antiviral (DAA) drug regimens work specifically in the context of HIV/HCV co-infection. In other words, the FOA is looking for innovative, multidisciplinary studies that can generate new insights and data where current evidence is limited, with the potential to shape future, larger research efforts and improve patient outcomes.
A major theme of the opportunity is understanding pathogenic interactions between HIV and hepatitis viruses, meaning the mechanisms through which the viruses may influence each other and affect disease progression. This can include questions about immune system changes, inflammation, viral replication dynamics, liver injury pathways, and other biological processes that could explain why co-infected individuals sometimes experience different clinical trajectories than those with only one infection. The FOA emphasizes multidisciplinary approaches, which signals that NIH is interested in proposals that combine perspectives and methods across fields such as infectious diseases, immunology, hepatology, pharmacology, epidemiology, behavioral science, and health services research, rather than staying within a single silo.
Another focus is co-morbidities associated with HIV/hepatitis co-infection. Co-morbidities can include liver-related outcomes (like fibrosis progression, cirrhosis, and hepatocellular carcinoma) as well as broader systemic issues potentially linked to chronic immune activation and inflammation, such as metabolic complications, renal disease, cardiovascular risk, neurocognitive impacts, and certain cancers. The FOA frames these topics as gaps in understanding, suggesting the program is looking for studies that clarify the prevalence, drivers, timing, and clinical significance of these co-occurring conditions in co-infected populations. Projects that identify risk factors, biomarkers, or mechanistic pathways that connect co-infection to downstream complications would generally align with this stated purpose.
The third highlighted area is the effectiveness of interferon-free DAA regimens for treating HIV/HCV co-infection. At the time of the FOA, interferon-free DAAs represented a major shift in hepatitis C treatment, and NIH signaled a need to understand how these regimens perform in real-world and clinically complex co-infected populations. This could involve evaluating treatment response, safety profiles, adherence challenges, drug-drug interactions with antiretroviral therapy, and outcomes across diverse patient groups. The wording points to practical, patient-centered evidence needs, not just efficacy in idealized settings, and it implies interest in research that can inform treatment strategies and clinical guidelines for co-infected individuals.
This opportunity is explicitly informed by priority areas in the 2011 HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis (Combating the Silent Epidemic of Viral Hepatitis). That linkage matters because it frames the FOA as part of a broader federal strategy to reduce the burden of viral hepatitis through better prevention, care access, and improved treatments, particularly for populations disproportionately affected. Aligning a proposal with those public health priorities would likely strengthen its relevance, since the FOA is positioned as a mechanism to generate evidence that supports national goals around hepatitis-related morbidity and mortality.
From an administrative and funding standpoint, this is an NIH R21 mechanism, which typically supports exploratory or developmental research rather than large, definitive trials. The announcement lists an estimated total funding amount of $275,000 and an award ceiling of $275,000, with no cost sharing or matching requirement. The FOA was posted on June 10, 2014, with an original and current closing date of May 7, 2017, and it was archived on June 7, 2017, meaning it is no longer active for new applications, but it remains useful as a reference for NIH priorities and the kinds of projects that were sought during that period.
Eligibility is broad and includes many types of domestic organizations such as public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), small businesses, for-profit entities other than small businesses, and a wide range of government entities (state, county, city/township, special districts, and certain housing authorities). Importantly, the FOA also allows participation by tribal governments and tribal organizations, and it explicitly includes foreign eligibility: non-U.S. entities (foreign organizations and foreign institutions) may apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by the NIH Grants Policy Statement. The eligibility section also calls out a variety of institution types often associated with serving underrepresented communities, such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities, along with faith-based and community-based organizations and U.S. territories or possessions.
The opportunity falls under NIH and is associated with multiple CFDA program areas spanning mental health, alcohol research, drug abuse, cancer research (across several subcategories), diabetes/digestive/kidney diseases, allergy and infectious diseases, and microbiology/infectious diseases. That spread reflects the real-world complexity of HIV and hepatitis co-infection, which touches infectious disease biology, liver disease, substance use, oncology risk, and broader chronic disease outcomes. Practically, it also signals that proposals could be relevant to multiple NIH institutes and centers, consistent with the "multidisciplinary" label and the cross-cutting health impacts of co-infection.
For applicants or readers seeking the original full announcement text, NIH provided an additional information link (grants.nih.gov, PAR-14-254). The contact listed for access or linking issues is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV, indicating that administrative help was centralized through NIH OER rather than a single program officer contact in the excerpted text.
FAQs: Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R21) (PAR-14-254)
What is this NIH funding opportunity?
This is an NIH discretionary research grant opportunity titled "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R21)" with Funding Opportunity Number PAR-14-254. It uses the NIH R21 mechanism to support exploratory, early-stage research projects.
What is the main goal of PAR-14-254?
The central goal is to address key unanswered scientific and clinical questions affecting people living with both HIV and viral hepatitis, with an emphasis on generating new insights and data where evidence is limited and helping shape future, larger research efforts.
What research areas does the FOA prioritize?
The announcement highlights three connected areas: (1) biological interactions between HIV and hepatitis viruses that may worsen disease, (2) co-morbidities and complications that occur in co-infected individuals and why they occur, and (3) how effective newer interferon-free, direct-acting antiviral (DAA) regimens are specifically for HIV/HCV co-infection.
What does "multidisciplinary" mean in the context of this FOA?
What kinds of HIV and hepatitis "pathogenic interactions" are of interest?
The FOA emphasizes understanding mechanisms through which HIV and hepatitis viruses may influence each other and affect disease progression. Examples mentioned include immune system changes, inflammation, viral replication dynamics, liver injury pathways, and other biological processes that could explain different clinical trajectories in co-infected individuals.
What co-morbidities are within scope for co-infection research?
The FOA frames co-morbidities as an important gap in understanding. Examples include liver-related outcomes such as fibrosis progression, cirrhosis, and hepatocellular carcinoma, as well as broader systemic issues potentially linked to chronic immune activation and inflammation (metabolic complications, renal disease, cardiovascular risk, neurocognitive impacts, and certain cancers).
What types of questions about co-morbidities does NIH want explored?
Based on the description, aligned projects would help clarify the prevalence, drivers, timing, and clinical significance of co-occurring conditions in co-infected populations. Studies that identify risk factors, biomarkers, or mechanistic pathways linking co-infection to downstream complications would fit the stated purpose.
What does the FOA say about interferon-free DAA regimens?
The FOA highlights the need to understand how interferon-free, direct-acting antiviral (DAA) regimens perform specifically in HIV/HCV co-infected populations, including real-world and clinically complex settings.
What outcomes related to DAA regimens are relevant under this FOA?
The description points to evaluating treatment response, safety profiles, adherence challenges, drug-drug interactions with antiretroviral therapy, and outcomes across diverse patient groups, with an emphasis on practical, patient-centered evidence needs.
How does this FOA connect to broader federal public health priorities?
This opportunity is explicitly informed by priority areas in the 2011 HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis (Combating the Silent Epidemic of Viral Hepatitis). That linkage frames the research as contributing evidence that supports national goals to reduce hepatitis-related morbidity and mortality, especially in disproportionately affected populations.
What grant mechanism is used, and what does that imply?
It is an NIH R21 mechanism, which is typically intended for exploratory or developmental research rather than large, definitive trials. The FOA emphasizes generating new insights and early-stage data that can inform future larger efforts.
How much funding is available under this FOA?
The announcement lists an estimated total funding amount of $275,000 and an award ceiling of $275,000. The description provided does not indicate additional tiers beyond that ceiling.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
When was PAR-14-254 posted, and what were the key dates?
The FOA was posted June 10, 2014. The original and current closing date listed is May 7, 2017. It was archived on June 7, 2017.
Is this funding opportunity still open for new applications?
No. It was archived on June 7, 2017, and is no longer active for new applications. The description notes it can still be useful as a reference for NIH priorities and the kinds of projects sought during that period.
Who is eligible to apply?
Eligibility is broad and includes many domestic organization types such as public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), small businesses, for-profit entities other than small businesses, and a wide range of government entities (state, county, city/township, special districts, and certain housing authorities).
Are tribal governments and tribal organizations eligible?
Yes. The eligibility section explicitly allows participation by tribal governments and tribal organizations.
Are non-U.S. (foreign) organizations eligible?
Yes. The FOA explicitly includes foreign eligibility: non-U.S. entities (foreign organizations and foreign institutions) may apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by the NIH Grants Policy Statement.
Does the FOA mention institutions that serve underrepresented communities?
Yes. It lists several institution types often associated with serving underrepresented communities, including HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities. It also includes faith-based and community-based organizations and U.S. territories or possessions.
Which NIH program areas or topics is this opportunity associated with?
The opportunity is associated with multiple CFDA program areas spanning mental health, alcohol research, drug abuse, cancer research (across several subcategories), diabetes/digestive/kidney diseases, allergy and infectious diseases, and microbiology/infectious diseases, reflecting the cross-cutting impacts of HIV and hepatitis co-infection.
Why does the FOA connect to so many CFDA areas?
HIV and viral hepatitis co-infection can involve infectious disease biology and treatment as well as liver disease outcomes, substance use considerations, oncology risk, and broader chronic disease complications, so proposals may naturally align with multiple NIH institutes and scientific areas.
Where can someone find the original NIH announcement?
The FOA provides an additional information link at grants.nih.gov for PAR-14-254.
Who is the contact for technical issues related to access or linking?
The contact listed for access or linking issues is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Does the excerpt provide a specific program officer contact?
No. In the information provided, administrative help is described as centralized through NIH OER rather than a single program officer contact.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Food and Nutrition Health
Next opportunity: Advancing National Public Health Institutes Globally
Previous opportunity: Multidisciplinary Studies of HIV and Viral Hepatitis Co Infection (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 254
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 254) also looked into and applied for these:
| Funding Opportunity |
|---|
| Long Term Outcomes of Bariatric Surgery Using Large Datasets (R01) Apply for PAR 14 262 Funding Number: PAR 14 262 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $500,000 |
| Advancing Interventions to Improve Medication Adherence (R01) Apply for PA 14 334 Funding Number: PA 14 334 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC CCs) (U01) Apply for RFA DK 14 027 Funding Number: RFA DK 14 027 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $270,000 |
| Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CSCPDPC CDMC) (U01) Apply for RFA DK 14 028 Funding Number: RFA DK 14 028 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $1,000,000 |
| Administrative Supplements for Common Basic Sociobehavioral Mechanisms and Processes that Facilitate or Impede Self Management of Chronic Conditions (Admin Supp) Apply for PA 15 122 Funding Number: PA 15 122 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $100,000 |
| Limited Competition for Renewal Applications Collaborating Centers of Excellence in Regulatory Science and Innovation (U01) Apply for RFA FD 15 009 Funding Number: RFA FD 15 009 Agency: Food Drug Administration Category: Education Food and Nutrition Health Funding Amount: $250,000 |
| Neuroimaging in Obesity Research (R01) Apply for RFA DK 08 009 Funding Number: RFA DK 08 009 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Endoscopic Clinical Research In Pancreatic And Biliary Diseases (R03) Apply for PAR 06 171 Funding Number: PAR 06 171 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $50,000 |
| Exploratory/Developmental Clinical Research Grants in Obesity (R21) Apply for PA 06 256 Funding Number: PA 06 256 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Diet, Epigenetic Events, and Cancer Prevention (R21) Apply for PA 06 413 Funding Number: PA 06 413 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $200,000 |
| Diet, Epigenetic Events, and Cancer Prevention (R03) Apply for PA 06 414 Funding Number: PA 06 414 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: $50,000 |
| Mechanisms of Alcohol and Drug InducedPancreatitis (R01) Apply for PA 07 067 Funding Number: PA 07 067 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Diet, Epigenetic Events, and Cancer Prevention (R01) Apply for PA 07 175 Funding Number: PA 07 175 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Application of Metabolomics for Translational and Biological Research (R01) Apply for PA 07 301 Funding Number: PA 07 301 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Application of Metabolomics for Translational and Biological Research (R21) Apply for PA 07 302 Funding Number: PA 07 302 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Development of Assays for High Throughput Drug Screening (R01) Apply for PA 07 320 Funding Number: PA 07 320 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Research on the Economics of Diet, Activity, and Energy Balance (R01) Apply for PA 08 078 Funding Number: PA 08 078 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| The Effect of Racial and Ethnic Discrimination/Bias on Health Care Delivery (R01) Apply for PA 08 083 Funding Number: PA 08 083 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R01) Apply for PA 08 243 Funding Number: PA 08 243 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Lab to Marketplace Tools for Brain and Behavioral Research (SBIR R43/R44) Apply for PA 08 071 Funding Number: PA 08 071 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 254", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.